Table of Contents
Volume 2013, Article ID 973710, 11 pages
Review Article

New Oral Anticoagulants in the Treatment of Pulmonary Embolism: Efficacy, Bleeding Risk, and Monitoring

1Department of Pharmaceutical Care Services, Bassett Medical Center, Cooperstown, NY 13326, USA
2Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA

Received 22 June 2012; Accepted 31 January 2013

Academic Editor: C. Arnold Spek

Copyright © 2013 Kelly M. Rudd and Elizabeth (Lisa) M. Phillips. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist therapy bridged with parenteral anticoagulants. The recent approval of new oral anticoagulants (NOACs: apixaban, dabigatran, and rivaroxaban) has generated significant interest in their role in managing venous thromboembolism, especially pulmonary embolism due to their improved pharmacokinetic and pharmacodynamic profiles, predictable anticoagulant response, and lack of required efficacy monitoring. This paper addresses the available literature, on-going clinical trials, highlights critical points, and discusses potential advantages and disadvantages of the new oral anticoagulants in patients with pulmonary embolism.